Clinical efficacy of Jiawei Yinchenhao decoction combined with ursodeoxycholic acid and probiotics in the management of nonalcoholic fatty liver disease

IF 1.3 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY

Arab Journal of Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-03-15 DOI:10.1016/j.ajg.2026.01.007

Dong Chen , Xinyu Li , Jinghao Fu , Yaohan Ma , Hanyue Jiang , Qiang Li

{"title":"Clinical efficacy of Jiawei Yinchenhao decoction combined with ursodeoxycholic acid and probiotics in the management of nonalcoholic fatty liver disease","authors":"Dong Chen , Xinyu Li , Jinghao Fu , Yaohan Ma , Hanyue Jiang , Qiang Li","doi":"10.1016/j.ajg.2026.01.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The study focused on evaluating the clinical effectiveness of Jiawei Yinchenhao decoction (JWYCH) combined with ursodeoxycholic acid (UDCA) and probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD).</div></div><div><h3>Methods</h3><div>Patients with NAFLD were divided into an observation group (JWYCH + UDCA + probiotics) and a control group (UDCA + probiotics). Clinical efficacy, liver function, blood lipids, oxidative stress indicators, inflammatory cytokines, gut microbiota composition, and adverse events were assessed before and after 4 weeks of treatment.</div></div><div><h3>Results</h3><div>The observation group demonstrated a significantly higher clinical effective rate (90.00 %) compared to the control group (71.67 %) (<em>P</em> < 0.05). Both groups showed improved gut flora (increased <em>Bifidobacterium</em> and <em>Lactobacillus</em>, decreased <em>Escherichia coli</em> and <em>Enterococcus</em>), reduced liver enzymes (ALT, AST), bilirubin (TBil), and lipid levels (TC, LDL-C), and attenuated oxidative stress (lower MDA, higher GSH-Px and SOD) and inflammatory markers (TGF-β, TNF-α, IL-8); the observation group exhibited greater improvements across all indicators than the control group (<em>P</em> < 0.05). Adverse reactions were minimal and comparable between groups.</div></div><div><h3>Conclusion</h3><div>JWYCH combined with UDCA and probiotics provides superior therapeutic benefits for NAFLD by improving liver function, modulating intestinal microbiota, reducing inflammation and oxidative stress, and enhancing lipid metabolism, with good safety. This integrated approach holds promise for broader clinical application.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"27 2","pages":"Pages 192-198"},"PeriodicalIF":1.3000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arab Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1687197926000079","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The study focused on evaluating the clinical effectiveness of Jiawei Yinchenhao decoction (JWYCH) combined with ursodeoxycholic acid (UDCA) and probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD).

Methods

Patients with NAFLD were divided into an observation group (JWYCH + UDCA + probiotics) and a control group (UDCA + probiotics). Clinical efficacy, liver function, blood lipids, oxidative stress indicators, inflammatory cytokines, gut microbiota composition, and adverse events were assessed before and after 4 weeks of treatment.

Results

The observation group demonstrated a significantly higher clinical effective rate (90.00 %) compared to the control group (71.67 %) (P < 0.05). Both groups showed improved gut flora (increased Bifidobacterium and Lactobacillus, decreased Escherichia coli and Enterococcus), reduced liver enzymes (ALT, AST), bilirubin (TBil), and lipid levels (TC, LDL-C), and attenuated oxidative stress (lower MDA, higher GSH-Px and SOD) and inflammatory markers (TGF-β, TNF-α, IL-8); the observation group exhibited greater improvements across all indicators than the control group (P < 0.05). Adverse reactions were minimal and comparable between groups.

Conclusion

JWYCH combined with UDCA and probiotics provides superior therapeutic benefits for NAFLD by improving liver function, modulating intestinal microbiota, reducing inflammation and oxidative stress, and enhancing lipid metabolism, with good safety. This integrated approach holds promise for broader clinical application.

查看原文本刊更多论文

加味银宸浩汤联合熊去氧胆酸及益生菌治疗非酒精性脂肪肝的临床疗效观察

目的：评价加味银陈好汤联合熊去氧胆酸及益生菌治疗非酒精性脂肪性肝病（NAFLD）的疗效。方法：将NAFLD患者分为观察组（JWYCH + UDCA +益生菌）和对照组（UDCA +益生菌）。评估治疗前后4周的临床疗效、肝功能、血脂、氧化应激指标、炎症因子、肠道菌群组成、不良事件。结果：观察组临床有效率（90.00 %）显著高于对照组（71.67%），差异有统计学意义（P < 0.05）。两组均改善了肠道菌群（双歧杆菌和乳酸杆菌增加，大肠杆菌和肠球菌减少），降低了肝酶（ALT、AST）、胆红素（TBil）和脂质水平（TC、LDL-C），减轻了氧化应激（MDA降低，GSH-Px和SOD升高）和炎症标志物（TGF-β、TNF-α、IL-8）；观察组患者各项指标均优于对照组（P < 0.05）。不良反应最小，组间具有可比性。结论：JWYCH联合UDCA和益生菌治疗NAFLD具有改善肝功能、调节肠道菌群、减轻炎症和氧化应激、促进脂质代谢的优势，且安全性较好。这种综合方法有望得到更广泛的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arab Journal of Gastroenterology Medicine-Gastroenterology

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Arab Journal of Gastroenterology (AJG) publishes different studies related to the digestive system. It aims to be the foremost scientific peer reviewed journal encompassing diverse studies related to the digestive system and its disorders, and serving the Pan-Arab and wider community working on gastrointestinal disorders.